Intelligence · Clinical Development
Pipeline search results
Programs matching “peritoneal” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 52 pipeline programs matching "peritoneal" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
ALKS 4230-007
Wuhan Createrna Science and Technology Co., Ltd
Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
1 trial -
APHP230864
Pari Pharma GmbH
Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy
1 trial -
CISPLATIN
Ningbo Cancer Hospital
Ovarian epithelial cancer : intraperitoneal resectable relapse
1 trial -
CO-338-087
pharmaand GmbH
Ovarian epithelial cancer, Malignant peritoneal neoplasm, advanced (FIGO stage III-IV), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer (who responded to front-line platinum-based chemotherapy), Fallopian tube cancer
1 trial -
CORT125134-556
CORCEPT THERAPEUTICS INC
Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
1 trial -
DS6000-109
Daiichi Sankyo
Platinum-resistant, high-grade serous ovarian cancer (OVC),high-grade endometrioid OVC, primary peritoneal cancer, or fallopian tube cancer
1 trial -
DUO-O/D081RC00001
AstraZeneca AB
Newly diagnosed advanced (FIGO stage III-IV) high grade epithelial ovarian, fallopian or primary peritoneal cancer
1 trial -
Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
The First People's Hospital of Lianyungang
Gastric Cancer
1 trial -
J5E-MC-JZXB
Eli Lilly Co.
Fallopian Tube Neoplasms, Peritoneal Neoplasms, Ovarian Neoplasms, Neoplasm Metastasis
1 trial -
MITO 33
Fondazione Telethon ETS
Recurrent ovarian, fallopian tube or primary peritoneal cancer
1 trial -
PIPAC_VEROne
Verona Pharma Ireland Limited
Gastric adenocarcinoma with peritoneal metastases
1 trial -
mitomycin C-based hyperthermic intraperitoneal chemotherapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Hepatocellular Carcinoma
1 trial -
-, Pred Forte 10 mg/ml colirio en suspensión
AbbVie Deutschland GmbH & Co. KG
platinum-resistant advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers.
1 trial -
2024-512318-16-00
Disc Medicine
Patients with colorectal peritoneal metastases with a PCI-score of 1-20
1 trial -
CA116-001
Bristol-Myers Squibb Australia Pty Ltd
Platinum-resistant High-grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
1 trial -
CDZR123A02101
Novartis Pharmaceuticals
advanced, solid, relapsed tumors / advanced tumors: human lymphomas / solid human tumor indications (urothelial carcinoma, or other advanced/metastatic solid tumors, ovarian clear cell cancer, endometrial carcinoma, lymphoma including peripheral T-cell Lymphoma and GCBDLBCL, malignant pleural or peritoneal mesothelioma, metastatic castration - resistant prostate cancer (mCRPC))
1 trial -
Cisplatin and Doxorubicin
Chinese University of Hong Kong
Gastric Cancer Peritoneal Metastases
1 trial -
D4880C00003
AstraZeneca AB
unresectable pleural or peritoneal malignant mesothelioma
1 trial -
IB 2021-01
The George Institute
Adult patients with treatment-naïve surgically non-metastatic and resectable primary retroperitoneal, limbs and trunk wall undifferentiated pleomorphic sarcomas.
1 trial -
ICO-2023-14
CERO THERAPEUTICS HOLDINGS, INC.
Patients with newly diagnosed advanced peritoneal metastasis from colon and colorectal junction cancer
1 trial -
IMGN151-1001
AbbVie Deutschland GmbH & Co. KG
Recurrent endometrial cancer, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer (EOC), recurrent cervical cancer
1 trial -
Intensive Intraperitoneal Therapy in Advanced Ovarian Cancer
The George Institute
Ovarian Cancer
1 trial -
Irinotecan Accord 20 mg/ml concentraat voor oplossing voor infusie
Disc Medicine
Gastric peritoneal metastases
1 trial -
KEYTRUDA 25 mg/mL concentrate for solution for infusion
Fondazione Telethon ETS
Recurrent, platinum-resistant, CPS >1 positive ovarian, Fallopian tube and primary peritoneal cancer patients
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.